The Combination of IL-6, PLR and Nail Psoriasis: Screen for the Early Diagnosis of Psoriatic Arthritis
Xiaoyang Liu,Yan Zhao,Zhanglei Mu,Yuan Jia,Chen Liu,Jianzhong Zhang,Lin Cai
DOI: https://doi.org/10.2147/CCID.S413853
2023-06-28
Abstract:Xiaoyang Liu, 1 Yan Zhao, 1 Zhanglei Mu, 1 Yuan Jia, 2 Chen Liu, 3 Jianzhong Zhang, 1 Lin Cai 1 1 Department of Dermatology, Peking University People's Hospital, Beijing, People's Republic of China; 2 Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, People's Republic of China; 3 Department of Clinical Laboratory, Peking University People's Hospital, Beijing, People's Republic of China Correspondence: Lin Cai, Department of Dermatology, Peking University People's Hospital, &num 11. Xizhimen South St, Beijing, 100044, People's Republic of China, Tel +8610 88325472, Fax +8610 88325474, Email Background: Early screening or timely prediction of psoriatic arthritis (PsA) are crucial. The study aimed to compare the clinical characteristics, cytokines and inflammation index between plaque psoriasis and PsA to explore their values in the early diagnosis of PsA. Methods: This was a case-control study in a single center from January 2021 to February 2023. The differences in clinical characteristics and laboratory examinations between PsA and plaque psoriasis were conducted. Patients with rheumatoid arthritis (RA) were used as a positive control. The correlation between variables were analyzed and multivariable logistic regression were performed by using the 10-fold cross-validation to find independently risk factors of plaque psoriasis that are developing PsA. Results: A total of 109 patients with plaque psoriasis (without joint damage), 47 patients with PsA and 41 patients with RA were enrolled in this study. The study found that the proportion of patients with elevated serum IL-6 levels, as well as the value of platelet to lymphocyte ratio (PLR) and systemic immune-inflammation index (SII), were significantly higher in patients with PsA and early PsA (PsA course ≤ 2 years) compared to those with plaque psoriasis (p< 0.05). After adjusting for age, gender, severity of skin lesions, and comorbidities (diabetes, hypertension, hyperlipidemia, hyperuricemia, and overweight/obesity), the study identified nail psoriasis (OR=4.35, 95% CI 1.67– 11.29, p< 0.002), elevated serum IL-6 (OR=6.78, 95% CI 2.34– 19.67, p< 0.001), and PLR (OR=8.37, 95% CI 2.97– 23.61, p< 0.001) as independent risk factors for PsA. A multivariable logistic regression analysis employing 10-fold cross-validation assessing the predictive association between the diagnosis of early PsA and the combination of IL-6, PLR, and nail psoriasis demonstrated that the area under the curve (AUC) was 0.84 (95% CI 0.77– 0.90) and the F1-score was 0.67 (95% CI 0.54– 0.80). Conclusion: The combination of elevated serum IL-6, PLR, and nail psoriasis can help to predict and screen the early stage of PsA. Keywords: biomarkers, IL-6, PLR, psoriasis, psoriatic arthritis Psoriatic arthritis (PsA) is an immune-mediated inflammatory disease affecting joints and entheses, and is strongly associated with psoriasis. The majority of patients, approximately 85% to 91.67%, experience psoriasis prior to the onset of arthritis by a span of 7 to 10 years. 1–3 This lag time creates a unique opportunity, particularly for dermatologists, to identify patients with an increased risk for developing PsA. Unfortunately, a delay in diagnosing PsA by 6 months resulted in a higher chance of peripheral erosive disease and poorer physical function. 4 Consequently, early screening or timely prediction of PsA are crucial. Non-rheumatologists may encounter challenges in accurately identifying PsA or inflammatory joint disease at the early stage. Screening for PsA markers among patients with psoriasis may aid in identifying the onset of PsA as early as possible. However, the specific early biomarkers for PsA remain unclear. Proinflammatory and proliferation mediators, such as interleukin (IL)-6, IL-8, IL-17, IL-22, IL-23, tumor necrosis factor (TNF)-α, interferon (IFN)-α, and IFN-γ have been proved to be involved in the pathogenesis of psoriasis, and some of these mediators have been targeted for drug development. 5,6 However, inhibitors targeting the IL-23/IL-17 axis significantly improve psoriasis outcomes, but their effects on PsA skeletal symptoms are not superior to TNF inhibitors. 1 Similarly, compared with placebo, IL-6 monoclonal antibody treatment significantly improved musculoskeletal manifestations (joint signs and symptoms, enthesitis, and dactylitis), but with minimal improvements in skin. 7 This disparity may be attributed to differential cytokine or chemokine expression between skin lesions and joint lesions. Pro-inflammatory cytokines such as IL-1, TNF-a, IL-6 and IL-17 induce the production of matr -Abstract Truncated-
dermatology